SUMMARY To evaluate the neural regulation of postprandial somatostatin release we studied the effect of blockade of (a) alpha-adrenergic and beta-adrenergic and (b) cholinergic receptors on the plasma somatostatin, gastrin and insulin responses to a standard meal in two groups of five fasting healthy male volunteers. Thymoxamine (0.1 mg/kg iv over two minutes then 10 mg/hour for two hours) and propranolol (0.15 mg/kg iv over two minutes, then 0-75 mg/kg/hour for two hours) were started just before eating while atropine (0.04 mg/kg/im) was given at 15 minutes on completion of the meal. There was a prompt and sustained rise in plasma somatostatin after a control meal in all experiments. This rise was arrested by atropine but not altered by either thymoxamine or propranolol. The plasma gastrin response to a meal was moderately enhanced by thymoxamine and markedly enhanced by atropine. Postprandial insulin release was not affected by alpha-or beta-adrenergic blockade but was abolished by atropine. The effect of atropine on the postprandial plasma somatostatin rise might have been mediated through reduction in gastric acidity or delay in gastric emptying. Hence we gave five fasting male volunteers an intraduodenal infusion of fat emulsion (25 calories in 30 minutes) on two occasions both alone and after atropine. Plasma somatostatin rose during the fat infusion alone and this rise was abolished by atropine. These data suggest that (a) cholinergic but not adrenergic mechanisms are important modulators of plasma somatostatin release after orally ingested and intraduodenally infused nutrients (b) atropine abolishes plasma somatostatin release independently of its effects on gastric acidity and motility and (c) are consistent with the hypothesis that atropine potentiates postprandial gastrin release through reduction of somatostatin mediated inhibition.
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Plasma somatostatin levels rise after a mixed meal in man.1 Although the site of origin of postprandial plasma somatostatin in man is uncertain, the stomach, pancreas, and upper small gut are the most likely sources. The neural mechanisms which control postprandial release of somatostatin in man are unknown. There is strong evidence, however, of adrenergic and cholinergic modulation of basal and stimulated release of somatostatin both in vitro and in vivo. Samols The present study was designed to investigate autonomic control of release of plasma somatostatin by food in man. The study comprised three parts. In part 1 we studied the effect of alpha-adrenergic blockade and beta-adrenergic blockade separately on postprandial release of plasma somatostatin. In part 2 we studied the effect of cholinergic blockade 683 on postprandial plasma somatostatin, and as we will describe, the postprandial rise was arrested. Because this alteration might have been mediated by reduction in gastric acidity, or delay in gastric emptying, in part 3 we proceeded to study the effect of a prior bolus of atropine on the plasma somatostatin response to an intraduodenal infusion of fat -a potent stimulus of plasma somatostatin release in man7 which is unlikely to be affected by changes in gastric acidity or motility. Tyrosine-somatostatin (4 pg/tube) was used as a tracer, together with a highly specific rabbit antisomatostatin anti-serum (1 in 150 000) which gives a sensitivity of 10 pg/ml plasma. The basal somatostatin levels recorded in part 3 differed from those in parts 1 and 2. This was due to a newly prepared somatostatin standard solution which gave higher numerical values.
Methods

STATISTICS
Results are expressed as mean±1 SEM. The Student's t test for paired data was used and p<0-05 considered significant.
Results
ADRENERGIC BLOCKADE
Systemic effects There were no consistent changes in pulse rate or blood pressure during or after an infusion of thymoxamine. The pulse rate fell in all subjects with the infusion of propranolol from a mean basal rate of 70±3 beats per minute to a nadir of 56±3 beats per minute. (p<0.01).
Responses to a meal Plasma glucose rose postprandially in all three experiments to respective peak values of 6.4±0-6 mU/l (saline) 6-8±0-5 mU/l (thymoxamine) and 6 40±0-3 mU/l (propranolol). There were no significant differences at any time point. Somatostatin ( Fig. 1) The basal plasma somatostatin concentrations were similar for each of the three experiments, the combined mean being 18±1 pg/ml. There was a prompt and sustained rise in plasma somatostatin after the meal on each occasion to peaks of 48±9 pg/ml (saline) (p<0-02 compared with basal); 57± 10 pg/ml (thymoxamine) (p<002 compared with basal) and 54±10 pg/ml (propranolol) (p<0.01 compared with basal). In the thymoxamine experiment the postprandial plasma somatostatin level significantly exceeded the saline control value at 150 minutes only, 57±10 pg/ml compared with 43±10 pg/ml (p<0-02). Propranolol caused no significant differences from the control responses at any time point.
ASSAYS -Gastrin
Blood glucose was measured by the neocuproine There was a prompt and sustained rise in plasma Intraduodenal infusion offat (Fig. 3) Somatostatin The basal somatostatin concentrations were similar in both experiments, the mean level being 50±6 pg/ml. During the infusion of fat alone plasma somatostatin levels rose promptly to a peak of 112±22 pg/ml at 30 minutes (p<002 compared with basal), and rapidly returned to basal levels after the completion of the infusion of fat. Before administration of atropine abolished this response and the differences between the atropine and control experiment reached significance at 30 minutes (p<005). Plasma gastrin did not change after intraduodenal infusion of fat either alone or after atropine. 
Discussion
This study has shown in man that cholinergic mechanisms are important in mediating postprandial plasma somatostatin release, but failed to demonstrate such a role for adrenergic mechanisms. There is no doubt that the doses of propranolol and atropine were pharmacological, as marked and consistent changes in pulse rate occurred. Although objective evidence of alpha-adrenergic blockade during infusion of thymoxamine was not available, the dose used was 1 x 102 times greater than that reported to attenuate the peripheral vasoconstrictive effect of noradrenaline in normal subjects.1" There are a number of possible explanations for the failure to show a clear involvement of either alpha-or beta-adrenergically mediated control of postprandial plasma somatostatin release, as has been suggested from animal studies. 2-4 These include differences between in vitro and in vivo models, species variation in responses and differing specificities of antibodies used in the assay of somatostatin. It is of interest that Epstein and Berelowitz failed to alter plasma somatostatin concentrations in man with infusion of isoprenaline or dopamine, while propranolol caused a slight decline in unstimulated plasma somatostatin. 12 A further possible factor may be the selectivity of thymoxamine for alpha-ladrenoceptors. 13 In the isolated perfused canine pancreas, however, somatostatin release is reduced by phenoxybenzamine which, like thymoxamine, also shows alpha-l-adrenoceptor selectivity. 2 The action of atropine on postprandial circulating somatostatin in the present study may be mediated through direct cholinergic blockade. Alternatively, it may be the indirect result of some other effect of cholinergic blockade, such as reduction -in gastric acid output or delay in gastric emptying. As atropine also abolished the plasma somatostatin response to an intradodenal infusion of fat, however, we suggest that its action in reducing the plasma somatostatin response to a luminal nutrient stimulus appears to be independent of its effects on gastric acidity or emptying, and is likely to be a direct result of cholinergic blockade. This contention is consistent with our data on the effect of intragastric and intraduodenal infusions of dilute hydrochloric acid on circulating somatostatin in man in which somatostatin concentrations were unchanged by intragastric acid infusions and rose moderatley only when grossly supraphysiological doses of acid were given intraduodenally.14 Thus acid per se is not a major stimulus of plasma somatostatin while the vagus nerve appears to directly mediate the release of plasma somatostatin after oral or intraduodenal nutrients. Similarly, vagotomy'5 and autonomic neuropathy'6 prevent the plasma somatostatin rise after insulin-induced hypoglycaemia.
Tfie regulation of gastrin release in man is complex and there is evidence to suggest both betaand alpha-adrenergic modulation. Exogenous adrenaline stimulates gastrin release and this is inhibited by beta-blockade in man.17 Propranalol reduces the plasma gastrin response to gastric distension in man. 18 Phentolamine, when given with atropine, but not when given alone increases the plasma gastrin response to this stimulus.18 The moderate increase in postprandial plasma gastrin during an infusion of thymoxamine but not propranolol in the present study suggests the participation of alpha-adrenergic mechanisms in postprandial gastrin release, but does not elucidate further the contribution if any of beta-adrenergic mechanisms.
Atropine augmented the plasma gastrin response to food confirming the work of other investigators. 19 20 The failure of thymoxamine to alter the postprandial release of plasma insulin differs from previous reports in man of enhancement by phentolamine of insulin release following intravenous or intraduodenal glucose,24 25 or intravenous arginine.26 As phentolamine is an antagonist at both alpha-1 and alpha-2-adrenoceptors, receptor selectivity may account for this discrepancy. Indeed Nakadate et al have suggested that in mice alpha-2 rather than alpha-iadrenoceptors influence plasma insulin levels.27 Propranolol has been reported to reduce the plasma insulin response to an oral or intraduodenal glucose load in man.24 25 It is not clear why beta-adrenergic blockade had no effect on plasma insulin responses to a meal in the present study. The 
